Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. (MBRX) filed an 8-K (Regulation FD disclosure) on May 13, 2026 to announce it is approaching the first unblinding of data from its pivotal Phase 2B/3 “MIRACLE” trial. The trial is testing Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The study includes two Annamycin dose arms plus cytarabine and a control arm receiving cytarabine plus placebo. The company reiterated it expects the first unblinding to occur prior to June 30, 2026. The press release is attached as Exhibit 99.1; no trial results were disclosed in the filing.

Key Details

• Filing: Form 8-K (Item 7.01 Regulation FD disclosure), dated May 13, 2026.
• Trial: Pivotal Phase 2B/3 “MIRACLE” trial for Annamycin + cytarabine in R/R AML.
• Design: Two Annamycin dose arms (each combined with cytarabine) vs. control arm of cytarabine + placebo.
• Timing: Company continues to expect first unblinding of data prior to June 30, 2026; no interim data were released in the 8-K.

Why It Matters A first unblinding is a major clinical milestone because it can reveal interim efficacy and safety signals that affect the trial’s next steps and the drug’s regulatory path. For investors, the event is a near-term clinical catalyst: the timing was confirmed by management and broadly disclosed under Regulation FD to ensure fair public access to the information. The 8-K did not include any trial results, so investors should wait for the actual unblinded data release for information that could meaningfully influence the company’s outlook.